Can iX Biopharma's new line help lift its limp stock?

SINGAPORE (Dec 15):  Catalist-listed iX Biopharma has launched a line of nutraceuticals – dietary supplements and fortified food products – that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs.

The products could also improve market sentiment toward its stock price, which hit an all-time low of 18.4 cents two months ago and is more than 50% off its IPO price two years ago.

The company’s key product, Wafermine, or ketamine in a sublingual wafer formulation, has the potential to be a star, in the face of a major backlash against opioids, particularly in the US.

---

Related Stories

• iX Biopharma completes first phase of its study for dementia-related agitation drug
• Broker's Digest: Spotify, NetLink NBN Trust, TDCX, iX Biopharma, StarHub
• PhillipCap slashes target price on iX Biopharma, but maintains ‘buy’ call

---